Jasper Therapeutics presents data from preclinical briquilimab studies

Jasper Therapeutics is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology, AAAAI, Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations. Each of the studies being presented utilized Jasper’s proprietary c-Kit Mouse, which was developed to enable direct testing of briquilimab across a number of disease models, overcoming the limitations of standard models which do not bind antibodies directed at the human c-Kit receptor. “We are excited to present promising preclinical results from multiple studies this year at AAAAI, which indicate that briquilimab may be able to mitigate the likelihood of severe allergic reaction and anaphylaxis,” said Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine. “Each of these studies was conducted using the Jasper c-Kit Mouse, which we believe enables the generation of preclinical data with superior clinical translatability, and in turn, informs our clinical development programs.”